Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sabrina Falkowski

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
Bulletin Du Cancer|January 1, 2019
Sabrina Falkowski
Therapeutic Drug Monitoring|March 27, 2019
Therapeutic Drug Monitoring of Everolimus in Oncology: Evidences and PerspectivesSabrina Falkowski, Jean-Baptiste Woillard
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|December 10, 2009
Radiodermatitis prevention with sucralfate in breast cancer: fundamental and clinical studiesSabrina Falkowski, Patrick Trouillas, Jean-Luc Duroux, et al.
The Gulf Journal of Oncology|April 3, 2018
Vaginal metastasis of renal clear-cell cancerAmel Rehailia-Blanchard, Adekube Morel, Chloé Rancoul, et al.
The Pharmacogenomics Journal|February 5, 2020
Effect of genetic polymorphisms in CYP3A4, CYP3A5, and m-TOR on everolimus blood exposure and clinical outcomes in cancer patientsStéphanie Bonnet, Sabrina Falkowski, Marine Deppenweiler, et al.
Pharmacological Research|May 6, 2017
Towards therapeutic drug monitoring of everolimus in cancer? Results of an exploratory study of exposure-effect relationshipMarine Deppenweiler, Sabrina Falkowski, Franck Saint-Marcoux, et al.
BMC Cancer|December 29, 2017
Common variants in glucuronidation enzymes and membrane transporters as potential risk factors for colorectal cancer: a case control studySabrina Falkowski, Jean-Baptiste Woillard, Deborah Postil, et al.
Cancers|November 13, 2021
First-Line Treatment of Metastatic Clear Cell Renal Cell Carcinoma: What Are the Most Appropriate Combination Therapies?Yann-Alexandre Vano, Sylvain Ladoire, Réza Elaidi, et al.
Bulletin Du Cancer|November 13, 2017
[Crossed perceptions about malnutrition in patients and their doctors in oncology]Bruno Raynard, Xavier Hébuterne, François Goldwasser, et al.
European Journal of Cancer (Oxford, England : 1990)|May 19, 2016
Clinical activity of sunitinib rechallenge in metastatic renal cell carcinoma-Results of the REchallenge with SUnitinib in MEtastatic RCC (RESUME) StudyStéphane Oudard, Lionnel Geoffrois, Aline Guillot, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Bulletin Du Cancer|January 1, 2019
Sabrina Falkowski
Therapeutic Drug Monitoring|March 27, 2019
Therapeutic Drug Monitoring of Everolimus in Oncology: Evidences and PerspectivesSabrina Falkowski, Jean-Baptiste Woillard
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|December 10, 2009
Radiodermatitis prevention with sucralfate in breast cancer: fundamental and clinical studiesSabrina Falkowski, Patrick Trouillas, Jean-Luc Duroux, et al.
The Gulf Journal of Oncology|April 3, 2018
Vaginal metastasis of renal clear-cell cancerAmel Rehailia-Blanchard, Adekube Morel, Chloé Rancoul, et al.
The Pharmacogenomics Journal|February 5, 2020
Effect of genetic polymorphisms in CYP3A4, CYP3A5, and m-TOR on everolimus blood exposure and clinical outcomes in cancer patientsStéphanie Bonnet, Sabrina Falkowski, Marine Deppenweiler, et al.
Pharmacological Research|May 6, 2017
Towards therapeutic drug monitoring of everolimus in cancer? Results of an exploratory study of exposure-effect relationshipMarine Deppenweiler, Sabrina Falkowski, Franck Saint-Marcoux, et al.
BMC Cancer|December 29, 2017
Common variants in glucuronidation enzymes and membrane transporters as potential risk factors for colorectal cancer: a case control studySabrina Falkowski, Jean-Baptiste Woillard, Deborah Postil, et al.
Cancers|November 13, 2021
First-Line Treatment of Metastatic Clear Cell Renal Cell Carcinoma: What Are the Most Appropriate Combination Therapies?Yann-Alexandre Vano, Sylvain Ladoire, Réza Elaidi, et al.
Bulletin Du Cancer|November 13, 2017
[Crossed perceptions about malnutrition in patients and their doctors in oncology]Bruno Raynard, Xavier Hébuterne, François Goldwasser, et al.
European Journal of Cancer (Oxford, England : 1990)|May 19, 2016
Clinical activity of sunitinib rechallenge in metastatic renal cell carcinoma-Results of the REchallenge with SUnitinib in MEtastatic RCC (RESUME) StudyStéphane Oudard, Lionnel Geoffrois, Aline Guillot, et al.
Pageof 2